RedHill Biopharma (RDHL) Asset Writedowns and Impairment (2017 - 2022)

RedHill Biopharma (RDHL) has 4 years of Asset Writedowns and Impairment data on file, last reported at $1.5 million in Q4 2022.

• Asset Writedowns and Impairment for Q4 2022 came in at $1.5 million, down 85.88% year-over-year; the trailing twelve-month figure through Dec 2022 was $6.0 million (down 62.93% YoY), and the FY2022 annual result was $6.0 million, down 62.93% from the prior year.
• Asset Writedowns and Impairment eased to $1.5 million in Q4 2022 per RDHL's latest filing, from $1.6 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $10.7 million in Q4 2021 and troughed at $1.1 million in Q1 2020.
• A 3-year average of $2.4 million and a median of $1.8 million in 2020 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2021 and 2022: Asset Writedowns and Impairment surged 417.28% in 2021, then sank 85.88% in 2022.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $2.1 million in 2020, then surged by 417.28% to $10.7 million in 2021, then slumped by 85.88% to $1.5 million in 2022.
• Business Quant data shows RDHL's Asset Writedowns and Impairment at $1.5 million in Q4 2022, $1.6 million in Q3 2022, and $1.3 million in Q2 2022.